FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
04 janv. 2022 07h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
16 déc. 2021 06h30 HE
|
Cullinan Oncology, Inc.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
13 déc. 2021 07h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
17 nov. 2021 09h15 HE
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF)
29 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
22 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients Responses were seen in patients with...
Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit
20 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
09 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Coherus BioSciences Announces Upcoming Medical Conference Presentations
08 sept. 2021 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data...
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
28 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting...